Hi cheri,
Perhaps slip up 2 found the same study:
http://www.ncbi.nlm.nih.gov/pubmed/20354132
It is quite small but the response rate is 67 "% in higher-risk MDS patients and that is good. Vidaza alone usually leads to a little more than 50 % responses and Revlimid alone still lower figures.
Kind regards
Birgitta-A